MX359201B - Polipeptidos que se unen al complemento humano 5 (c5). - Google Patents

Polipeptidos que se unen al complemento humano 5 (c5).

Info

Publication number
MX359201B
MX359201B MX2014009879A MX2014009879A MX359201B MX 359201 B MX359201 B MX 359201B MX 2014009879 A MX2014009879 A MX 2014009879A MX 2014009879 A MX2014009879 A MX 2014009879A MX 359201 B MX359201 B MX 359201B
Authority
MX
Mexico
Prior art keywords
polypeptides
join
human complement
amino acid
acid sequence
Prior art date
Application number
MX2014009879A
Other languages
English (en)
Other versions
MX2014009879A (es
Inventor
Berghard Charlotta
Berglund Magnus
Strömberg Patrik
Lindborg Malin
Gunneriusson Elin
Feldwisch Joachim
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MX2014009879A publication Critical patent/MX2014009879A/es
Publication of MX359201B publication Critical patent/MX359201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)

Abstract

La presente invención se refiere a polipéptidos de unión a C5, que comprende un motivo de unión a C5, BM, cuyo motivo consiste de una secuencia de aminoácido seleccionada de i) EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX25 X26LX28D, y ii) una secuencia de aminoácido que tiene al menos 86% de identidad con la secuencia definida en i), en donde el polipéptido se une a C5. La presente invención además se refiere a polipéptidos de unión a C5 para utilizarse en terapia, tal como para el uso en el tratamiento de una afección relacionada con C5, y a métodos de tratamientos.
MX2014009879A 2012-02-20 2013-02-19 Polipeptidos que se unen al complemento humano 5 (c5). MX359201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1250145 2012-02-20
PCT/SE2013/050139 WO2013126006A1 (en) 2012-02-20 2013-02-19 Polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
MX2014009879A MX2014009879A (es) 2014-11-10
MX359201B true MX359201B (es) 2018-09-19

Family

ID=49006055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009879A MX359201B (es) 2012-02-20 2013-02-19 Polipeptidos que se unen al complemento humano 5 (c5).

Country Status (31)

Country Link
US (5) US9808502B2 (es)
EP (3) EP3511339B1 (es)
JP (2) JP6276202B2 (es)
KR (2) KR102336895B1 (es)
CN (1) CN104114574B (es)
AU (3) AU2013222836B2 (es)
BR (1) BR112014020427B1 (es)
CA (1) CA2863862C (es)
CY (1) CY1121455T1 (es)
DK (1) DK2817329T3 (es)
ES (1) ES2715638T3 (es)
HR (1) HRP20190522T1 (es)
HU (1) HUE041996T2 (es)
IL (2) IL234114B (es)
LT (1) LT2817329T (es)
ME (1) ME03640B (es)
MX (1) MX359201B (es)
MY (1) MY167232A (es)
NZ (1) NZ628625A (es)
PH (1) PH12014501604B1 (es)
PL (1) PL2817329T3 (es)
PT (1) PT2817329T (es)
RS (1) RS58503B1 (es)
RU (1) RU2654668C2 (es)
SG (1) SG11201404942UA (es)
SI (1) SI2817329T1 (es)
SM (1) SMT201900189T1 (es)
TR (1) TR201903840T4 (es)
UA (1) UA117096C2 (es)
WO (1) WO2013126006A1 (es)
ZA (1) ZA201406773B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2817329T3 (en) * 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
EP2912051B1 (en) 2012-10-25 2018-04-18 Affibody AB Method for the separation of proteins containing an albumin-binding domain
WO2014064237A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Abd binding polypeptide
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
KR102503319B1 (ko) 2014-06-12 2023-02-28 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
KR101787003B1 (ko) 2014-06-13 2017-10-18 애피바디 에이비 신규한 폴리펩티드
JP7028557B2 (ja) * 2014-06-13 2022-03-02 アフィボディ アクティエボラーグ 新規ポリペプチド
DE102014225439A1 (de) * 2014-12-10 2016-06-16 Zf Friedrichshafen Ag Stufenplanet
MY188784A (en) * 2015-01-12 2021-12-31 Affibody Ab Il-17a-binding polypeptides
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
BR112019028269A2 (pt) * 2017-07-11 2020-07-14 Alexion Pharmaceuticals, Inc. polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
WO2020198778A1 (en) 2019-04-03 2020-10-08 Clean Earth Technology Pty Ltd Materials and processes for recovering precious metals
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
CA2186108A1 (en) 1994-03-23 1995-09-28 Scott A. Rollins Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP0777474B1 (en) 1994-09-23 2005-12-21 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU2001296594A1 (en) 2000-10-10 2002-04-22 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7432356B2 (en) * 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2323692T3 (es) 2002-12-02 2009-07-23 Resistentia Holding Ab Metodos y materiales para tratar afecciones inflamatorias usando un polipeptido que comprende un segmento de aminoacidos c5 autogenicos y un segmento de aminoacidos no autogenicos.
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2526083C (en) 2003-06-02 2017-01-17 Evolutec Limited Complement inhibitors
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005090381A1 (en) 2004-03-24 2005-09-29 Auckland Uniservices Limited Set1 proteins and uses therefor
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
NZ594285A (en) * 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
BRPI0708909B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc uso de um anticorpo que se liga a c5 para tratar um paciente que sofre de hemoglobinúria paroxística noturna
WO2008010902A2 (en) 2006-07-06 2008-01-24 The Trustees Of The University Of Pennsylvania Regulation of tlr signaling by complement
US9388235B2 (en) 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
US7947277B2 (en) * 2006-09-08 2011-05-24 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
CN101932337A (zh) 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
WO2009016043A2 (en) 2007-07-31 2009-02-05 Affibody Ab New albumin binding compositions, methods and uses
WO2009030240A2 (en) 2007-09-05 2009-03-12 Immunobond Aps Method of determining functional deficiencies in the complement system
US9187535B2 (en) * 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
SI2328616T1 (sl) 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
HRP20230167T1 (hr) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
RU2015145543A (ru) 2010-03-01 2019-01-11 Алексион Фармасьютикалз Инк. Способы и композиции для лечения болезни дего
US20110243942A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Relaxin-fusion proteins with extended in vivo half-lives
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
EP2590993B1 (en) 2010-07-09 2015-05-06 Affibody AB Polypeptides
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
WO2014096163A1 (en) 2012-12-19 2014-06-26 Affibody Ab New polypeptides
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
ZA201406773B (en) 2016-08-31
HRP20190522T1 (hr) 2019-05-03
SG11201404942UA (en) 2014-09-26
HUE041996T2 (hu) 2019-07-29
TR201903840T4 (tr) 2019-04-22
RU2014137303A (ru) 2016-04-10
PH12014501604A1 (en) 2014-10-08
MY167232A (en) 2018-08-14
EP4616914A2 (en) 2025-09-17
JP6276202B2 (ja) 2018-02-07
JP2015508652A (ja) 2015-03-23
CA2863862C (en) 2021-03-16
US9808502B2 (en) 2017-11-07
US20250332214A1 (en) 2025-10-30
CY1121455T1 (el) 2020-05-29
KR102149028B1 (ko) 2020-08-27
SMT201900189T1 (it) 2019-05-10
AU2013222836A1 (en) 2014-09-18
EP2817329A1 (en) 2014-12-31
DK2817329T3 (en) 2019-04-01
US10206975B2 (en) 2019-02-19
IL234114B (en) 2019-07-31
AU2017245376A1 (en) 2017-11-02
BR112014020427A8 (pt) 2018-01-23
AU2019250239A1 (en) 2019-11-07
US11123401B2 (en) 2021-09-21
AU2013222836B2 (en) 2017-07-20
UA117096C2 (uk) 2018-06-25
US20180085428A1 (en) 2018-03-29
CA2863862A1 (en) 2013-08-29
KR20140129163A (ko) 2014-11-06
EP3511339A1 (en) 2019-07-17
MX2014009879A (es) 2014-11-10
CN104114574B (zh) 2018-08-24
EP3511339B1 (en) 2025-04-09
EP2817329A4 (en) 2015-09-02
LT2817329T (lt) 2019-04-10
ES2715638T3 (es) 2019-06-05
HK1204790A1 (en) 2015-12-04
EP4616914A3 (en) 2025-11-19
PT2817329T (pt) 2019-04-01
KR102336895B1 (ko) 2021-12-08
JP2018052942A (ja) 2018-04-05
JP6719438B2 (ja) 2020-07-08
ME03640B (me) 2020-07-20
US20210401930A1 (en) 2021-12-30
IL267724A (en) 2019-08-29
AU2019250239B2 (en) 2021-04-08
CN104114574A (zh) 2014-10-22
RS58503B1 (sr) 2019-04-30
US12083160B2 (en) 2024-09-10
SI2817329T1 (sl) 2019-04-30
EP2817329B1 (en) 2019-01-02
WO2013126006A1 (en) 2013-08-29
PL2817329T3 (pl) 2019-07-31
KR20200105953A (ko) 2020-09-09
AU2017245376B2 (en) 2019-07-25
IL267724B (en) 2022-05-01
RU2654668C2 (ru) 2018-05-21
PH12014501604B1 (en) 2018-11-07
US20150011474A1 (en) 2015-01-08
NZ628625A (en) 2016-03-31
US20190167760A1 (en) 2019-06-06
BR112014020427B1 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
EA201792245A1 (ru) Биоконъюгаты и их применения
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
EA201591559A1 (ru) Терапевтические пептиды
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
EA201792307A1 (ru) Способы репарации и регенерации тканей
BR112016029318A2 (pt) tratamento de mielomas
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
ES2526109R2 (es) Péptido y composición farmacéutica para el tratamiento del cáncer

Legal Events

Date Code Title Description
FG Grant or registration